Corsair Partnering Corp - Quarter Report: 2022 March (Form 10-Q)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
For the period ended March 31, 2022
OR
☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
For the transition period from to
CORSAIR PARTNERING CORPORATION
(Exact name of registrant as specified in its charter)
Cayman Islands
|
001-40285 |
|
(State or other jurisdiction of incorporation or organization)
|
(Commission File Number) |
(I.R.S. Employer Identification Number)
|
717 Fifth Avenue, 24th Floor
New York,
|
10022
|
|
(Address of principal executive offices)
|
(Zip Code)
|
(212) 244-9400
Registrant’s telephone number, including area code:
Not Applicable
(Former name or former address, if changed since last report)
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
|
Trading
Symbol(s)
|
Name of each exchange
on which registered
|
||
Class A Ordinary Shares, par value $0.0001
|
CORS
|
The New York Stock Exchange
|
||
Redeemable warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50
|
CORS WS
|
The New York Stock Exchange
|
||
Units, each consisting of one Class A ordinary share and one-third of one redeemable warrant
|
CORS.U
|
The New York Stock Exchange
|
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was
required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such
shorter period that the registrant was required to submit such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated
filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer
|
☐ |
Accelerated filer
|
☐ |
Non-accelerated filer
|
☒ |
Smaller reporting company
|
☒ |
Emerging growth company
|
☒ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☒ No ☐
As of May 13, 2022, 28,090,000 Class A ordinary shares, par value $0.0001 per share, 250,000 Class B ordinary shares, par value $0.0001 per share, and 1,404,500 Class F ordinary
shares, par value $0.0001 per share, were issued and outstanding.
Page
|
||
PART I. FINANCIAL INFORMATION
|
||
Item 1.
|
1
|
|
1
|
||
2
|
||
3
|
||
4
|
||
5
|
||
Item 2.
|
20
|
|
Item 3.
|
26
|
|
Item 4.
|
26
|
|
PART II. OTHER INFORMATION
|
||
Item 1.
|
27
|
|
Item 1A.
|
27
|
|
Item 2.
|
27
|
|
Item 3.
|
27
|
|
Item 4.
|
27
|
|
Item 5.
|
27
|
|
Item 6.
|
28
|
|
Signatures |
29 |
CONDENSED
BALANCE SHEETS
|
March 31, 2022
|
December 31, 2021
|
||||||
Assets: |
(Unaudited)
|
|||||||
Current assets:
|
||||||||
Cash
|
$
|
537,030
|
$
|
881,821
|
||||
Prepaid expenses
|
496,020
|
605,633
|
||||||
Due from related party
|
8,992
|
-
|
||||||
Total current assets
|
1,042,042
|
1,487,454
|
||||||
Investments held in Trust Account
|
281,016,296
|
280,950,832
|
||||||
Total Assets
|
$
|
282,058,338
|
$
|
282,438,286
|
||||
|
||||||||
Liabilities, Class A Ordinary Shares Subject to Possible Redemption and Shareholders' Deficit:
|
||||||||
Current liabilities:
|
||||||||
Accounts payable
|
$
|
17,548
|
$
|
142,310
|
||||
Accrued expenses
|
311,471
|
198,520
|
||||||
Due to related party
|
-
|
2,581
|
||||||
Total current liabilities
|
329,019
|
343,411
|
||||||
Derivative warrant liabilities
|
6,205,640
|
14,977,206
|
||||||
Deferred underwriting commissions in connection with the initial public offering
|
9,831,500
|
9,831,500
|
||||||
Total liabilities
|
16,366,159
|
25,152,117
|
||||||
|
||||||||
Commitments and Contingencies
|
||||||||
|
||||||||
Class A ordinary shares subject to possible redemption; $0.0001 par value; 28,090,000 shares at
redemption value of $10.00 per share as of March 31, 2022 and December 31, 2021
|
280,900,000
|
280,900,000
|
||||||
|
||||||||
Shareholders' Deficit:
|
||||||||
Preference shares, $0.0001
par value; 1,000,000 shares authorized; none issued and outstanding as of March 31, 2022 and December 31, 2021
|
-
|
-
|
||||||
Class A ordinary shares, $0.0001 par value; 380,000,000 shares authorized; no non-redeemable shares issued or outstanding as of March 31, 2022 and December 31, 2021
|
-
|
-
|
||||||
Class B ordinary shares, $0.0001 par value; 1,000,000 shares authorized; 250,000 shares issued and outstanding as of March 31, 2022 and December 31, 2021
|
25
|
25
|
||||||
Class F ordinary shares, $0.0001 par value; 50,000,000 shares authorized; 1,404,500 shares issued and outstanding as of March 31, 2022 and December 31, 2021
|
141
|
141
|
||||||
Additional paid-in capital
|
-
|
-
|
||||||
Accumulated deficit
|
(15,207,987
|
)
|
(23,613,997
|
)
|
||||
Total shareholders' deficit
|
(15,207,821
|
)
|
(23,613,831
|
)
|
||||
Total Liabilities, Class A Ordinary Shares Subject to Possible Redemption and
Shareholders' Deficit
|
$
|
282,058,338
|
$
|
282,438,286
|
The
accompanying notes are an integral part of these unaudited condensed financial statements.
UNAUDITED CONDENSED
STATEMENTS OF OPERATIONS
|
For the Three Months Ended March 31, 2022
|
For the Period from January 1, 2021 (Commencement of Operations) through March 31, 2021
|
||||||
|
||||||||
General and administrative expenses
|
$
|
431,020
|
$
|
34,020
|
||||
Loss from operations
|
(431,020
|
)
|
(34,020
|
)
|
||||
Other income (expenses):
|
||||||||
Change in fair value of derivative warrant liabilities
|
8,771,566
|
-
|
||||||
Income from investments held in Trust Account
|
65,464
|
-
|
||||||
Net income (loss)
|
$
|
8,406,010
|
$
|
(34,020
|
)
|
|||
|
||||||||
Weighted average number of shares outstanding of Class A ordinary shares, basic
and diluted
|
28,090,000
|
-
|
||||||
Basic and diluted net income per share, Class A ordinary shares
|
$
|
0.28
|
$
|
-
|
||||
Weighted average number of shares outstanding of Class B ordinary shares, basic
and diluted
|
250,000
|
230,556
|
||||||
Basic and diluted net income (loss) per share, Class B ordinary shares
|
$
|
0.28
|
$
|
(0.02
|
)
|
|||
Weighted average number of shares outstanding of Class F ordinary shares, basic
and diluted
|
1,404,500
|
1,152,778
|
||||||
Basic and diluted net income (loss) per share, Class F ordinary shares
|
$
|
0.28
|
$
|
(0.02
|
)
|
The accompanying notes are an integral part of these unaudited condensed financial statements.
UNAUDITED CONDENSED STATEMENTS OF CHANGES IN SHAREHOLDERS’ DEFICIT
FOR THE THREE MONTHS ENDED MARCH 31, 2022
|
Ordinary shares
|
Additional Paid-In
Capital
|
Accumulated
Deficit
|
Total Shareholders'
Deficit
|
||||||||||||||||||||||||||||||||
|
Class A
|
Class B
|
Class F
|
|||||||||||||||||||||||||||||||||
|
Shares
|
Amount
|
Shares
|
Amount
|
Shares
|
Amount
|
||||||||||||||||||||||||||||||
Balance - December 31, 2021
|
-
|
$
|
-
|
250,000
|
$
|
25
|
1,404,500
|
$
|
141
|
$
|
-
|
$
|
(23,613,997
|
)
|
$
|
(23,613,831
|
)
|
|||||||||||||||||||
Net income
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
8,406,010
|
8,406,010
|
|||||||||||||||||||||||||||
Balance - March 31, 2022 (unaudited)
|
-
|
$
|
-
|
250,000
|
$
|
25
|
1,404,500
|
$
|
141
|
$
|
-
|
$
|
(15,207,987
|
)
|
$
|
(15,207,821
|
)
|
PERIOD FROM JANUARY 1, 2021 (COMMENCEMENT OF OPERATIONS) THROUGH MARCH 31, 2021
Ordinary shares |
Additional Paid-In Capital
|
Accumulated Deficit
|
Total Shareholder’s Deficit
|
|||||||||||||||||||||||||||||||||
Class A |
Class B |
Class F | ||||||||||||||||||||||||||||||||||
|
Shares | Amount | Shares | Amount | Shares | Amount | ||||||||||||||||||||||||||||||
Balance – January 1, 2021
|
- |
$ | - | - |
$ | - | - |
$ | - | $ | - | $ | - | $ | - | |||||||||||||||||||||
Issuance of Class B ordinary shares to Sponsor
|
- |
- |
250,000
|
25 |
- |
- |
18,725
|
- |
18,750
|
|||||||||||||||||||||||||||
Issuance of Class F ordinary shares to Sponsor
|
- |
- | - |
- |
1,437,500
|
144 |
6,106 |
- |
6,250
|
|||||||||||||||||||||||||||
Net loss
|
-
|
- |
-
|
- |
-
|
- |
- |
(34,020
|
)
|
(34,020 | ) | |||||||||||||||||||||||||
Balance - March 31, 2021 (unaudited)
|
- |
$ | - |
250,000
|
$ | 25 |
1,437,500
|
$
|
144
|
$
|
24,831
|
$
|
(34,020
|
)
|
$
|
(9,020
|
)
|
The accompanying notes are an integral part of these unaudited condensed financial statements.
UNAUDITED CONDENSED STATEMENTS OF
CASH FLOWS
|
For the Three Months Ended March 31, 2022
|
For the Period from January 1, 2021 (Commencement of Operations) through March 31, 2021
|
||||||
Cash Flows from Operating Activities:
|
||||||||
Net income (loss)
|
$
|
8,406,010
|
$
|
(34,020
|
)
|
|||
Adjustments to reconcile net income (loss) to net cash used in operating activities:
|
||||||||
General and administrative expenses paid by related party in exchange for issuance of Class B and Class F ordinary shares
|
-
|
25,000
|
||||||
Income on investments from Trust Account
|
(65,464 | ) | - | |||||
Due to related party
|
(11,573
|
)
|
719
|
|||||
Change in fair value of derivative warrant liabilities
|
(8,771,566
|
)
|
-
|
|||||
Changes in operating assets and liabilities:
|
||||||||
Prepaid expenses
|
109,613
|
-
|
||||||
Accounts payable
|
(124,762
|
)
|
-
|
|||||
Accrued expenses
|
112,951
|
8,301
|
||||||
Net cash used in operating activities
|
(344,791
|
)
|
-
|
|||||
|
||||||||
Cash Flows from Financing Activities:
|
||||||||
Proceeds from note payable to related party
|
-
|
25,100
|
||||||
Net cash provided by financing activities
|
-
|
25,100
|
||||||
|
||||||||
Net change in cash
|
(344,791
|
)
|
25,100
|
|||||
Cash - beginning of the period
|
881,821
|
-
|
||||||
Cash - end of the period
|
$
|
537,030
|
$
|
25,100
|
||||
|
||||||||
Supplemental disclosure of noncash financing activities:
|
||||||||
Offering costs included in accounts payable
|
$
|
-
|
$
|
23,175
|
||||
Offering costs included in accrued expenses
|
$
|
-
|
$
|
370,000
|
||||
Offering cost paid by related party under promissory note
|
$
|
-
|
$
|
144,771
|
The accompanying notes are an integral part of these unaudited condensed financial statements.
4
NOTE 1. ORGANIZATION AND
BUSINESS OPERATIONS
Incorporation
Corsair Partnering Corporation (the “Company”) was incorporated as a Cayman Islands exempted company on December 29, 2020 and commenced
operations on January 1, 2021.
Sponsor
The Company’s Sponsor is Corsair Partnering Sponsor LP, a Cayman Islands limited partnership (the “Sponsor”). On January 8, 2021, an affiliate of the
Company temporarily subscribed for (a) 2,300,000 Founder Shares (as defined in Note 4) in exchange for a capital contribution of $6,250, or approximately $0.0027
per share and (b) 120,000 Class B Performance Shares (as defined in Note 4) for a capital contribution of $18,750, or approximately $0.1563
per share and on January 21, 2021 (x) exchanged 130,000 Founder Shares on a one for one basis for Performance Shares and (y) surrendered 157,500 Founder Shares. Such Founder Shares and Performance Shares were assigned to the Sponsor on January 28, 2021. On April 30, 2021, the Sponsor surrendered 575,000 Founder Shares for no
consideration, such that there were 1,437,500 Founder Shares and 250,000 Performance Shares issued and outstanding (with up to 187,500
Founder Shares subject to forfeiture depending on the extent to which the Underwriters’ Over-Allotment Option was exercised). On July 15, 2021 the underwriter purchased an additional 3,090,000 Units pursuant to the partial exercise of the over-allotment option. As a result, the Sponsor subsequently forfeited 33,000 Class F ordinary shares on July 15, 2021 and there are 1,404,500 Class F ordinary shares outstanding as of March 31, 2022 and December 31, 2021. All shares and associated amounts have been retroactively
restated to reflect the share exchange and the share surrenders.
Business Purpose
The Company was formed for the purpose of identifying a company to partner with, in order to effectuate a merger, share exchange, asset
acquisition, share purchase, reorganization or similar partnering transaction with one or more businesses (the “Partnering Transaction”). The Company may pursue a Partnering Transaction in any business or industry but expect to focus on a
business where the Company believes its strong network, operational background, and aligned economic structure will provide the Company with a competitive advantage. The Company has not generated revenue to date.
The Company’s management has broad discretion with respect to the specific application of the net proceeds of its Initial Public Offering
as described below, although substantially all of the net proceeds of the Initial Public Offering are intended to be generally applied toward completing a Partnering Transaction. Furthermore, there is no assurance that the Company will be
able to successfully complete a Partnering Transaction.
Financing
The registration statement for the Company’s Initial Public Offering was declared effective on
June 30, 2021. On July 6, 2021, the
Company consummated its Initial Public Offering of 25,000,000 units (the “Units” and,
with respect to the Class A ordinary shares included in the Units being offered, the “Public Shares”), at $10.00 per Unit, generating gross proceeds of $250.0 million, and
incurring offering costs of approximately $14.4 million, of which approximately $8.8 million and approximately $481,000 was for deferred underwriting commissions (see Note 5) and offering costs allocated to derivate warrant
liabilities, respectively. On July 15, 2021, the underwriters purchased an additional 3,090,000 Units (the “Option Units”) pursuant to the partial exercise of the over-allotment option. The Option Units were sold at an
offering price of $10.00 per Unit, generating additional gross proceeds to the Company
of $30.9 million. The Company
incurred additional offering cost of approximately $1.7 million in connection with the over-allotment, of which approximately $1.1 million was for deferred underwriting commissions and approximately $55,000 was offering costs allocated to derivative warrant liabilities.
5
Simultaneously with the closing of the Initial Public Offering, the Company consummated
the private placement (“Private Placement”) of 5,000,000 warrants (each, a “Private Placement Warrant” and collectively, the
“Private Placement Warrants”) at a price of $1.50 per Private Placement Warrant to the Sponsor, generating proceeds of $7.5 million. In connection with the exercise of the over-allotment option on July 15, 2021, the Sponsor purchased an additional 412,000 Private Placement Warrants at a purchase price of $1.50
per Private Placement Warrant, generating additional gross proceeds to the Company of $618,000 (see Note 4).
Trust Account
Upon the closing of the Initial Public Offering and the Private Placement, $280.9 million ($10.00 per Unit, and including $30,900,000 in connection with the underwriters’ partial exercise of the
over-allotment option) of the net proceeds of the sale of the Units in the Initial Public Offering and of the Private Placement Warrants in the Private Placement were placed in a trust account (“Trust Account”), located in the United States
and will be invested only in United States “government securities” within the meaning of Section 2(a)(16) of the Investment Company Act of 1940, as amended (the “Investment Company Act”) having a maturity of 185 days or less or in money
market funds meeting certain conditions under Rule 2a-7 promulgated under the Investment Company Act which invest only direct U.S. government treasury obligations, until the earlier of: (i) the completion of a Partnering Transaction and
(ii) the distribution of the Trust Account as described below.
The Company must complete a Partnering Transaction with one or more partner candidate businesses having an aggregate fair market value of at least 80% of the net assets held in the Trust Account (excluding the taxes payable on the income earned on the Trust Account) at the time of the agreement to enter into the initial
Partnering Transaction. However, the Company will only complete a Partnering Transaction if the post-transaction company owns or acquires 50%
or more of the voting securities of the partner candidate or otherwise acquires a controlling interest in the
partner candidate sufficient for it not to be required to register as an investment company under the Investment Company Act.
The Company’s Amended and Restated Memorandum and Articles of Association (the “Amended and Restated Memorandum and
Articles of Association”) provides that, other than the withdrawal of interest earned on the funds that may be released to the Company for withdrawals to pay taxes including income and franchise taxes and to withdraw up to $100,000 in dissolution expenses in the event the Company does not complete the Partnering Transaction within the Partnering Period (as defined
below), none of the funds held in the Trust Account will be released until the earlier of: (i) the completion of the Partnering Transaction; (ii) the redemption of any of the Public Shares by its holders (the “Public Shareholders”)
properly tendering Public Shares in connection with a shareholder vote to amend certain provisions of the Company’s Amended and Restated Memorandum and Articles of Association prior to a Partnering Transaction or (iii) the redemption of 100% of the Public Shares if the Company does not complete a Partnering Transaction within the Partnering Period (defined below).
The Company, after signing a definitive agreement for a Partnering Transaction, will either (i) seek shareholder approval of the Partnering
Transaction at a meeting called for such purpose in connection with which Public Shareholders may seek to redeem their Public Shares, regardless of whether they vote for or against the Partnering Transaction or do not vote at all, for cash
equal to their pro rata share of the aggregate amount then on deposit in the Trust Account calculated as of As a result, such ordinary
shares subject to possible redemption were recorded at redemption amount and classified as temporary equity, in accordance with FASB, ASC 480, “Distinguishing Liabilities from Equity.” The amount in the Trust Account was initially at
$10.00 per Public Share. The decision as to whether the Company will seek shareholder approval of the Partnering Transaction or
will allow shareholders to sell their shares in a tender offer will be made by the Company, solely in its discretion, and will be based on a variety of factors such as the timing of the transaction and whether the terms of the transaction
would otherwise require the Company to seek shareholder approval. If the Company seeks shareholder approval, it will complete its Partnering Transaction only if a majority of the outstanding ordinary shares voted are voted in favor of the
Partnering Transaction. However, in no event will the Company redeem its Public Shares in an amount that would cause its net tangible assets to be less than $5,000,001 immediately prior to or upon consummation of the Company’s initial Partnering Transaction. In such case, the Company would not proceed with the redemption of its Public
Shares and the related Partnering Transaction, and instead may search for an alternate Partnering Transaction. business days
prior to the consummation of the initial Partnering Transaction, including interest earned on the funds held in the Trust Account and not previously released to the Company to pay its taxes, or (ii) provide the Public Shareholders with the
opportunity to sell their shares to the Company by means of a tender offer (and thereby avoid the need for a shareholder vote) for an amount in cash equal to their pro rata share of the aggregate amount then on deposit in the Trust Account
calculated as of business days prior to commencement of the tender offer, including interest earned on the funds held in the
Trust Account and not previously released to the Company to pay its taxes.
6
The Company will only have 24 months (or 27 months if the
Company has executed a letter of intent, agreement in principle or definitive agreement for the Partnering Transaction within 24
months) from the closing of the Initial Public Offering to complete its initial Partnering Transaction (the “Partnering Period”). If the Company does not complete a Partnering Transaction within this period of time (and shareholders do not
approve an amendment to the Amended and Restated Memorandum and Articles of Association to extend this date), it will (i) cease all operations except for
the purpose of winding up, (ii) as promptly as reasonably possible but not more than business days thereafter, redeem the
Public Shares, at a per-share price, payable in cash, of $10.00, and (iii) as promptly as reasonably possible following such
redemption, subject to the approval of our remaining shareholders and our board of directors, liquidate and dissolve, subject in the case of clauses (ii) and (iii), to our obligations under Cayman Islands law to provide for claims of
creditors and in all cases subject to the other requirements of applicable law.
The holders of the Founder Shares immediately prior to the
Initial Public Offering (the “Initial Shareholders”) entered into a Letter Agreement with the Company, pursuant to which they agreed to (i) waive their redemption rights with respect to any Founder Shares (as defined in Note 4) and Public
Shares they hold in connection with the completion of the Partnering Transaction, (ii) waive their redemption rights with respect to any Founder Shares and Public Shares they hold in connection with a shareholder vote to approve an amendment
to the Company’s Amended and Restated Memorandum and Articles of Association to modify the substance or timing of the Company’s obligation to redeem 100%
of its Public Shares if the Company has not consummated a Partnering Transaction within the Partnering Period or with respect to any other material provisions relating to shareholders’ rights or pre-Partnering Transaction activity and (iii)
waive their rights to liquidating distributions from the Trust Account with respect to any Founder Shares they hold if the Company fails to complete the Partnering Transaction within 24 months of the Partnering Period (although they will be entitled to liquidating distributions from the Trust Account with respect to any Public Shares they hold if the
Company fails to complete the Partnering Transaction within the Partnering Period).
Pursuant to the Letter Agreement, the Sponsor agreed that
it will be liable to the Company if and to the extent any claims by a third party for services rendered or products sold to the Company, or a prospective target business with which the Company has entered into a written letter of intent,
confidentiality or other similar agreement or Partnering Transaction agreement, reduce the amount of funds in the Trust Account to below the lesser of (i) $10.00 per Public Share and (ii) the actual amount per Public Share held in the Trust Account as of the date of the liquidation of the Trust Account, if less than $10.00 per Public Share due to reductions in the value of the Trust assets, less taxes payable, provided that such liability will not apply to any
claims by a third party or prospective target business who executed a waiver of any and all rights to the monies held in the Trust Account (whether or not such waiver is enforceable) nor will it apply to any claims under the Company’s
indemnity of the underwriters of the Initial Public Offering against certain liabilities, including liabilities under the Securities Act (as defined below).
Emerging Growth Company
The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act of 1933, as amended (the “Securities Act”), as modified by the Jumpstart our Business Startups Act of 2012 (the
“JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to
comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of
holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved.
Further, section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have
not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides
that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such an election to opt out is irrevocable. The Company has elected not to opt out of
such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, we, as an emerging growth company, can adopt the new or revised standard at the
time private companies adopt the new or revised standard. This may make comparison of the Company’s condensed financial statements with another public company which is neither an emerging growth company nor an emerging growth company which
has opted out of using the extended transition period difficult or impossible because of the potential differences in accountant standards used.
7
Risks and Uncertainties
Management continues to evaluate the impact of the COVID-19 pandemic and has concluded that
while it is reasonably possible that the virus could have a negative effect on the Company’s financial position, results of its operations and /or search for a partner candidate company, the specific impact is not readily determinable as
of the date of these condensed financial statements. The condensed financial statements do not include any adjustments that might result from the outcome of this uncertainty.
In February 2022, the Russian Federation and Belarus commenced a military action with the country of Ukraine. As a result of this action, various nations, including the United States, have instituted economic
sanctions against the Russian Federation and Belarus. Further, the impact of this action and related sanctions on the world economy are not determinable as of the date of these condensed financial statements. The specific impact on
the Company’s financial condition, results of operations, and cash flows is also not determinable as of the date of these condensed financial statements.
Liquidity and Capital Resources
As of March 31, 2022, the Company had approximately $537,000 in its operating bank account and working capital of approximately $713,000.
The Company’s liquidity needs prior to the consummation of the Initial Public Offering were satisfied through the payment of $25,000 from related parties to cover certain expenses on the Company’s behalf in exchange for issuance of Founder Shares and Performance
Shares (as defined in Note 4), a loan from the Sponsor under the Note (as defined in Note 4) of approximately $231,000, and an
advance from the Sponsor of $750,000 to be used in case the over-allotment option was exercised in full by the underwriters.
The Company repaid the Note balance of approximately $231,000 on July 6, 2021. Subsequent to the consummation of the Initial
Public Offering, the Company’s liquidity has been satisfied through the net proceeds from the consummation of the Initial Public Offering and the Private Placement held outside of the Trust Account. In addition, in order to finance
transaction costs in connection with a Partnering Transaction, the Sponsor or an affiliate of the Sponsor, or certain of the Company’s officers and directors may, but are not obligated to, provide the Company Working Capital Loans (as
defined in Note 4). As of March 31, 2022 and December 31, 2021, there were no amounts outstanding under any Working
Capital Loan.
Based on the foregoing, management believes that the Company will have sufficient working capital and borrowing capacity to meet its needs
through the earlier of the consummation of a Partnering Transaction or one year from this filing. Over this time period, the Company will be using the funds held outside of the Trust Account for paying existing accounts payable,
identifying and evaluating prospective initial Partnering Transaction candidates, performing due diligence on prospective target businesses, paying for travel expenditures, selecting the target business to merge with or acquire, and
structuring, negotiating and consummating the Partnering Transaction.
NOTE 2. SIGNIFICANT ACCOUNTING POLICIES
Basis of Presentation
The accompanying unaudited condensed financial statements are presented in U.S. dollars in conformity with accounting principles generally
accepted in the United States of America (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X and pursuant to the rules and regulations of the SEC. Accordingly, certain disclosures
included in the annual financial statements have been condensed or omitted from these condensed financial statements as they are not required for interim financial statements under GAAP and the rules of the SEC. In the opinion of management,
the unaudited condensed financial statements reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the balances and results for the period presented. Operating results for the three
months ended March 31, 2022, and since inception are not necessarily indicative of the results that may be expected through December 31, 2022, or any future period.
The accompanying unaudited condensed financial statements should be read in conjunction with the audited financial statements and notes
thereto included in the Annual Report on Form 10-K filed by the Company with the SEC on March 29, 2022.
8
Cash and Cash Equivalents
The Company considers all short-term investments with an original maturity of three months or
less when purchased to be cash equivalents. The Company had no cash equivalents held as of March 31, 2022 and December 31,
2021.
Investments Held in Trust Account
The Company’s portfolio of investments held in the
Trust Account is comprised of U.S. government securities, within the meaning set forth in Section 2(a)(16) of the Investment Company Act, with a maturity of 185 days or less, or investments in money market funds that invest in U.S.
government securities, or a combination thereof. When the Company’s investments held in the Trust Account are comprised of U.S. government securities, the investments are classified as trading securities. Trading securities and investments
in money market funds are presented on the condensed balance sheets at fair value at the end of each reporting period. Gains and losses resulting from the change in fair value of these securities is included in income from investments held
in Trust Account in the accompanying unaudited condensed statements of operations. The estimated fair values of investments held in the Trust Account are determined using available market information.
Concentration of Credit Risk
Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial
institution, which, at times, may exceed the Federal Deposit Insurance Corporation coverage of $250,000 and investments held in the Trust Account. As of March 31, 2022 and December 31, 2021, the Company has not experienced losses on
these accounts and management believes the Company is not exposed to significant risks on such accounts.
Fair Value of Financial Instruments
The fair value of the Company’s assets and
liabilities which qualify as financial instruments under FASB ASC 820, “Fair Value Measurements and Disclosures,” equal or approximate the carrying amounts represented in the condensed balance sheets, primarily due to their short-term
nature.
Fair Value Measurements
Fair value is defined as the price that would be received for sale of an asset or paid for
transfer of a liability, in an orderly transaction between market participants at the measurement date. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the
highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers consist of:
• |
Level 1, defined as observable inputs such as quoted prices (unadjusted) for identical
instruments in active markets;
|
• |
Level 2, defined as inputs other than quoted prices in active markets that are either
directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and
|
• |
Level 3, defined as unobservable inputs in which little or no market data exists,
therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.
|
In some circumstances, the inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In those
instances, the fair value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement.
9
Use of Estimates
The preparation of condensed financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts
of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed financial statements and the reported amounts of income and expenses during the reporting period. Making estimates requires management
to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the condensed financial statements, which management considered
in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.
Offering Costs Associated with the Initial Public Offering
Offering costs consisted of legal, accounting, underwriting fees and other costs incurred through the Initial Public Offering that were
directly related to the Initial Public Offering. Offering costs were allocated to the separable financial instruments issued in the Initial Public Offering based on a relative fair value basis, compared to total proceeds received. Offering
costs associated with derivative warrant liabilities were expensed as incurred and presented as non-operating expenses in the unaudited condensed statements of operations. Offering costs associated with the Class A ordinary shares issued
were charged against the carrying value of the Class A ordinary shares subject to possible redemption upon the completion of the Initial Public Offering including exercise of over-allotment option. The Company classifies deferred
underwriting commissions as non-current liabilities as their liquidation is not reasonably expected to require the use of current assets or require the creation of current liabilities.
Derivative Warrant Liabilities
The Company does not use derivative instruments to
hedge exposures to cash flow, market, or foreign currency risks. The Company evaluates all of its financial instruments, including issued share purchase warrants, to determine if such instruments are derivatives or contain features that
qualify as embedded derivatives, pursuant to ASC 480 and FASB ASC Topic 815, “Derivatives and Hedging” (“ASC 815”). The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as
equity, is re-assessed at the end of each reporting period.
The Public Warrants and the Private Placement Warrants are recognized as derivative liabilities in accordance with ASC 815.
Accordingly, the Company recognizes the warrant instruments as liabilities at fair value and adjusts the carrying value of the instruments to fair value at each reporting period until they are exercised. The initial fair value of the
Public Warrants issued in connection with the Initial Public Offering were estimated using a Monte-Carlo simulation model. The fair value of the Public Warrants as of March 31, 2022 and December 31, 2021 is based on observable listed
prices for such warrants. The fair value of the Private Placement Warrants as of March 31, 2022 and December 31, 2021 is determined using a Black-Scholes option pricing model. The determination of the fair value of the warrant liability
may be subject to change as more current information becomes available and accordingly the actual results could differ significantly. Derivative warrant liabilities are classified as non-current liabilities as their liquidation is not
reasonably expected to require the use of current assets or require the creation of current liabilities.
Class A Ordinary Shares Subject to Possible
Redemption
The Company accounts for its Class A ordinary shares subject to possible redemption in accordance with the guidance in ASC Topic 480 “Distinguishing
Liabilities from Equity.” Class A ordinary shares subject to mandatory redemption (if any) are classified as liability instruments and are measured at fair value. Conditionally redeemable Class A ordinary shares (including Class A
ordinary shares that features redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) are classified as temporary
equity. At all other times, Class A ordinary shares are classified as shareholders’ equity. The Company’s Class A ordinary shares feature certain redemption rights that are considered to be outside of the Company’s control and subject
to the occurrence of uncertain future events. Accordingly, as of March 31, 2022 and December 31, 2021, 28,090,000 Class
A ordinary shares subject to possible redemption are presented at redemption value as temporary equity, outside of the shareholders’ equity section of the Company’s condensed balance sheets.
10
Under ASC 480-10-S99, the Company has elected to recognize changes in the redemption value immediately as they occur and adjust the carrying value of the
security to equal the redemption value at the end of the reporting period. This method would view the end of the reporting period as if it were also the redemption date of the security. Effective with the closing of the Initial Public
Offering (including exercise of the over-allotment option), the Company recognized the accretion from initial book value to redemption amount, which resulted in charges against additional paid-in capital (to the extent available) and
accumulated deficit.
Net Income (Loss) Per Ordinary Share
The Company complies with accounting and
disclosure requirements of FASB ASC Topic 260, “Earnings Per Share.” The Company has three classes of shares, which are referred to as Class A ordinary shares, Class B ordinary shares, and Class F ordinary shares. Income and losses
are shared pro rata between the three classes of shares. This presentation assumes a business combination as the most likely outcome. Net income (loss) per ordinary share is calculated by dividing the net income (loss) by the weighted
average shares of ordinary shares outstanding for the respective period.
The calculation of diluted net income (loss)
per ordinary share does not consider the effect of the warrants issued in connection with the Initial Public Offering (including exercise of the over-allotment option) and the Private Placement to purchase an aggregate of 14,775,333 Class A ordinary shares in the calculation of diluted income (loss) per ordinary share, because their exercise is contingent
upon future events and their inclusion would be anti-dilutive under the treasury stock method. As a result, diluted net income (loss) per ordinary share is the same as basic net income (loss) per share for the three months ended March
31, 2022 and for the period from January 1, 2021 (commencement of operations) through March 31, 2021. Accretion associated with the redeemable Class A ordinary shares is excluded from earnings per share as the redemption value
approximates fair value.
The following table reflects a reconciliation
of the numerator and denominator used to compute basic and diluted net income (loss) per share for each class of ordinary share:
For the Three Months Ended March 31, 2022
|
For the Period from January 1, 2021 (Commencement of Operations) through March 31, 2021
|
|||||||||||||||||||||||
Class A
|
Class B
|
Class F
|
Class A
|
Class B
|
Class F
|
|||||||||||||||||||
Basic and diluted net income (loss) per ordinary share:
|
||||||||||||||||||||||||
Numerator:
|
||||||||||||||||||||||||
Allocation of net income (loss)
|
$
|
7,938,436
|
$
|
70,652
|
$
|
396,922
|
$
|
-
|
$
|
(5,670
|
)
|
$
|
(28,350
|
)
|
||||||||||
Denominator:
|
||||||||||||||||||||||||
Basic and diluted weighted average ordinary shares outstanding
|
28,090,000
|
250,000
|
1,404,500
|
-
|
230,556
|
1,152,778
|
||||||||||||||||||
Basic and diluted net income (loss) per ordinary share
|
$
|
0.28
|
$
|
0.28
|
$
|
0.28
|
$
|
-
|
$
|
(0.02
|
)
|
$
|
(0.02
|
)
|
Income Taxes
FASB ASC Topic 740 “Income Taxes,” prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax
positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. The Company’s management determined that the
Cayman Islands is the Company’s only major tax jurisdiction. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts
accrued for interest and penalties as of March 31, 2022 and December 31, 2021. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position.
11
There
is currently no taxation imposed on income by the Government of the Cayman Islands. In accordance with Cayman federal income tax regulations, income taxes are not levied on the Company. Consequently, income taxes are not reflected in the
Company’s condensed financial statements. The Company’s management does not expect that the total amount of unrecognized tax benefits will materially change over the next twelve months.
Recent Accounting
Pronouncements
Management does not believe that any
recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company’s condensed financial statements.
NOTE 3. INITIAL
PUBLIC OFFERING
On July 6, 2021, the Company
consummated its Initial Public Offering of 25,000,000 Units, at $10.00 per Unit, generating gross proceeds of $250.0
million, and incurring offering costs of approximately $14.4 million, of which approximately $8.8 million and approximately $481,000
was for deferred underwriting commissions and offering costs allocated to derivate warrant liabilities, respectively. Of the 25,000,000
Units sold in the Initial Public Offering, 1,000,000 Units with respect to which no underwriting discount is payable were
purchased by certain parties. On July 15, 2021, the underwriters purchased an additional 3,090,000
Units pursuant to the partial exercise of the over-allotment option. The over-allotment units were sold at an offering price of $10.00
per Unit, generating additional gross proceeds to the Company of $30.9 million. The Company incurred additional offering cost
of approximately $1.7 million in connection with the over-allotment, of which approximately $1.1 million was for deferred underwriting commissions.
Each Unit consists of one Class A ordinary share, and
of one redeemable warrant (each, a “Public Warrant”). Each Public Warrant entitles the holder to purchase one Class A ordinary
share at a price of $11.50 per share, subject to adjustment.NOTE 4. RELATED PARTY TRANSACTIONS
Founder Shares and
Performance Shares
On January 8, 2021, an affiliate of the Company paid for
certain expenses on behalf of the Company (a) of $6,250 in exchange for 2,300,000 Class F ordinary shares (the “Founder Shares”), and (b) of $18,750
in exchange for 120,000 Class B ordinary shares (the “Performance Shares”). On January 21, 2021, such affiliate surrendered 157,500 Class F ordinary shares and exchanged 130,000
Class F ordinary shares for a corresponding number of Class B ordinary shares by way of repurchase of each Class F ordinary share at par and applying such repurchase consideration for the payment of the Class B ordinary shares. Such Founder
Shares and Performance Shares were assigned to the Sponsor on January 28, 2021. On April 30, 2021 the Sponsor surrendered 575,000
Founder Shares for no consideration. Of the 1,437,500 Founder Shares then outstanding, up to 187,500 of the Founder
Shares were subject to forfeiture depending on the extent to which the underwriters’ over-allotment is exercised. The Founder Shares are entitled to (together with the Performance Shares) a number of votes representing 20% of the Company’s outstanding ordinary share capital prior to the completion of the Partnering Transaction. On July 15, 2021, the underwriters purchased an additional 3,090,000 Units pursuant to the partial exercise of the over-allotment option. As a result, the Sponsor subsequently forfeited 33,000 Class F ordinary shares such that there are 1,404,500 Class F ordinary shares outstanding as of the date hereof.
The Initial Shareholders agreed not to transfer, assign or
sell (i) any of its Performance Shares except to any permitted transferees which will be subject to the same restrictions and other agreements of the Sponsor with respect to any Founder Shares, and (ii) any of its Class A ordinary shares
deliverable upon conversion of the Performance Shares for 2 years following the completion of the Partnering Transaction. In
connection with this arrangement, the Sponsor will also agree not to transfer, assign or sell any of its Founder Shares until the earlier to occur of: (i) 180 days after the completion of the Partnering Transaction and (ii) the date on which the Company completes a liquidation, merger, share capital exchange or other similar transaction
after the Partnering Transaction that results in all of the Company’s shareholders having the right to exchange their Class A ordinary shares for cash, securities or other property; except to certain permitted transferees and under certain
circumstances as described herein. Any permitted transferees will be subject to the same restrictions and other agreements of the Initial Shareholders with respect to any Founder Shares.
12
Private Placement
Warrants
Simultaneously with the closing of the Initial Public Offering on July 6, 2021, the Company consummated the Private
Placement of 5,000,000 Private Placement Warrants at a price of $1.50 per Private Placement Warrant to the Sponsor, generating proceeds of $7.5
million. In connection with the exercise of the over-allotment option on July 15, 2021, the Sponsor purchased an additional 412,000 Private Placement Warrants at a purchase price of $1.50
per Private Placement Warrant, generating additional gross proceeds to the Company of $618,000.
Each whole Private Placement Warrant is exercisable for one whole Class A ordinary share at a price of $11.50
per share. A portion of the proceeds from the Private Placement Warrants was added to the proceeds from the Initial Public Offering held in the Trust Account. If the Company does not complete a Partnering Transaction within the Partnering
Period, the Private Placement Warrants will expire worthless. The Private Placement Warrants will be non-redeemable and exercisable on a cashless basis so long as they are held by the Sponsor or its permitted transferees. The Sponsor and the
Company’s officers and directors agreed, subject to limited exceptions, not to transfer, assign or sell any of their Private Placement Warrants until 30
days after the completion of the initial Partnering Transaction.
Related Party Loans
On January 8,
2021, an affiliate of the Sponsor agreed to loan the Company up to an aggregate of $300,000 pursuant to an unsecured promissory
note (the “Note”). This loan was payable without interest upon the completion of the Initial Public Offering. As of June 30, 2021, the Company borrowed approximately $231,000 under the Note and repaid the Note in full on July 6, 2021. Subsequent to the repayment, the facility is no longer available to the Company.
In addition,
on July 1, 2021, the Company received an advance from the Sponsor of $750,000 to be used in case the over-allotment option was
exercised in full by the underwriters. On July 15, 2021, in connection with the exercise of the over-allotment option, the Sponsor purchased an additional 412,000 Private Placement Warrants at a purchase price of $1.50 per
Private Placement Warrant generating proceeds of $618,000 and the remaining advance of $132,000 was returned to the Sponsor.
In order to finance transaction costs in connection with a
Partnering Transaction, the Sponsor or an affiliate of the Sponsor, or certain of the Company’s officers and directors may, but are not obligated to, loan the Company funds as may be required (“Working Capital Loans”). If the Company completes
a Partnering Transaction, the Company will repay the Working Capital Loans out of the proceeds of the Trust Account released to the Company. Otherwise, the Working Capital Loans would be repaid only out of funds held outside the Trust Account.
In the event that a Partnering Transaction does not close, the Company may use a portion of the proceeds held outside the Trust Account to repay the Working Capital Loans but no proceeds held in the Trust Account would be used to repay the
Working Capital Loans. Except for the foregoing, the terms of such Working Capital Loans, if any, have not been determined and no written agreements exist with respect to such loans. The Working Capital Loans would either be repaid upon
consummation of a Partnering Transaction, without interest, or, at the lender’s discretion, up to $1.5 million of such Working
Capital Loans may be convertible into warrants of the post Partnering Transaction entity at a price of $1.50 per warrant. The
warrants would be identical to the Private Placement Warrants. As of March 31, 2022 and December 31, 2021, the Company had no
borrowings under the Working Capital Loans.
Administrative
Services Agreement
On June 30,
2021, the Company entered into an agreement with the Sponsor providing that, commencing on the date that the Company’s securities were first listed on the NYSE through the earlier of consummation of the Partnering Transaction and the
Company’s liquidation, the Company may agree to pay an affiliate of the Sponsor for office space, secretarial and administrative services provided to members of the Company’s management team $15,000 per month. $45,000 and $0, respectively, have been incurred
and paid for the three months ended March 31, 2022 and for the period from January 1, 2021 (commencement of operations) through March 31, 2021. There
were no balances outstanding as of March 31, 2022, and December 31, 2021.
In addition, the Sponsor, its executive officers and
directors, and any of their respective affiliates will be reimbursed for any out-of-pocket expenses incurred in connection with activities on the Company’s behalf such as identifying potential partnering candidates and performing due diligence
on suitable Partnering Transactions. The Company’s audit committee will review on a quarterly basis all payments that were made to the Sponsor, executive officers or directors, or the Company or their affiliates. As of March 31, 2022, and
December 31, 2021, we had a receivable of approximately $9,000 and a payable of $2,000, respectively, in due to related party for such expense reimbursement.
13
NOTE
5. COMMITMENTS AND CONTINGENCIES
Forward Purchase Agreement
On June 30, 2021, we entered into a
Forward Purchase Agreement with an affiliate, Corsair V Financial Services Capital Partners, L.P., pursuant to which such investor committed to purchase in the aggregate, up to 10,000,000 units, with each unit consisting of one Class
A ordinary share and of one warrant to purchase one Class A ordinary share at $11.50 per share, subject
to adjustment, at a purchase price of $10.00 per unit, in private placements to occur concurrently, and only in connection with,
the closing of our initial Partnering Transaction. The obligations of the investor under the Forward Purchase Agreement will not depend on whether any Class A Ordinary Shares are redeemed by our Public Shareholders. The obligations of such
investor to purchase the Forward Purchase Securities are subject to the approval, prior to our entering into a definitive agreement for our initial Partnering
Transaction, of its investment committee and the Forward Purchase Agreement contains customary closing conditions. The Forward Purchase Agreement is not a firm commitment by either party to the agreement. The proceeds from the sale of
Forward Purchase Securities, if any, may be used as part of the consideration to the sellers in the initial Partnering Transaction, expenses in connection with the initial Partnering Transaction or for working capital in the
post-transaction company.
Registration and Shareholder Rights
The holders of the Founder Shares, Performance Shares, Forward Purchase Securities, Private
Placement Warrants and private placement warrants that may be issued upon conversion of Working Capital Loans (and any Class A ordinary shares issuable upon the exercise of the Private Placement Warrants, and private placement warrants may be
issued upon conversion of Working Capital Loans and upon conversion of the Founder Shares and the Performance Shares) were entitled to registration rights pursuant to a registration rights agreement signed upon the effective date of the Initial Public Offering, requiring the Company to register such securities for resale. The holders of these
securities are entitled to make up to three demands, excluding short form demands, that the Company registers such securities. In
addition, the holders have certain “piggy-back” registration rights with respect to registration statements filed subsequent to the completion of the Partnering Transaction. The Company will bear the expenses incurred in connection with the
filing of any such registration statements.
Pursuant to the Forward Purchase Agreement, the Company expects to agree to use its reasonable best efforts (i) to file within 30 days after the closing of the initial Partnering Transaction a registration statement with the SEC for a secondary offering of the Forward Purchase Shares and the
Forward Purchase Warrants (and underlying Class A ordinary shares), (ii) to cause such registration statement to be declared effective promptly thereafter but in no event later than 60 days after the initial filing, (iii) to maintain the effectiveness of such registration statement until the earliest of (A) the date on which the Forward Purchasers or
its assignees cease to hold the securities covered thereby and (B) the date all of the securities covered thereby can be sold publicly without restriction or limitation under Rule 144 under the Securities Act and (iv) after such registration
statement is declared effective, cause the Company to conduct firm commitment underwritten offerings, subject to certain limitations. In addition, the Forward Purchase Agreement provides for certain “piggy-back” registration rights to the
holders of Forward Purchase Securities to include their securities in other registration statements filed by the Company.
Underwriting Agreement
The Company granted the underwriters a 45-day option from the date of the final prospectus relating to the Initial Public Offering to purchase up to 3,750,000
additional Units to cover over-allotments, if any, at the Initial Public Offering price less the underwriting discounts and commissions. On July 15, 2021, the underwriters purchased an additional 3,090,000 Option Units pursuant to the partial exercise of the over-allotment option. The Option Units were sold at an offering price of $10.00 per Unit, generating additional gross proceeds to the Company of $30,900,000.
14
Except for the 1,000,000
Units purchased by certain parties in the Initial Public Offering, the underwriters were entitled to an underwriting discount of $0.20
per unit, or $5.4 million in the aggregate, paid upon the closing of the Initial Public Offering and exercise of the over-allotment option.
In addition, $0.35
per unit, or approximately $9.8 million in the aggregate will be payable to the underwriters for deferred underwriting commissions.
The deferred fee will become payable to the underwriters from the amounts held in the Trust Account solely in the event that the Company completes a Partnering Transaction, subject to the terms of the underwriting agreement.
NOTE 6. CLASS A ORDINARY
SHARES SUBJECT TO POSSIBLE REDEMPTION
The Company’s Class A
ordinary shares feature certain redemption rights that are considered to be outside of the Company’s control and subject to the occurrence of future events. The Company is authorized to issue 380,000,000 Class A ordinary shares with a par value of $0.0001
per share. Holders of the Company’s Class A ordinary shares are entitled to one vote for each share. As of March 31, 2022 and December
31, 2021, there were 28,090,000 Class A ordinary shares outstanding subject to possible redemption.
The Class A ordinary
shares subject to possible redemption reflected on the condensed balance sheets is reconciled on the following table:
Gross proceeds
|
$
|
280,900,000
|
||
Less:
|
||||
Fair value of Public Warrants at issuance
|
(9,082,433
|
)
|
||
Offering costs allocated to Class A ordinary shares subject to possible redemption
|
(15,555,759
|
)
|
||
Plus:
|
||||
Accretion on Class A ordinary shares subject to possible redemption amount
|
24,638,192
|
|||
Class A ordinary shares subject to possible redemption
|
$
|
280,900,000
|
NOTE 7.
SHAREHOLDERS’ DEFICIT
Preference
Shares-The Company is authorized to issue 1,000,000 preference shares with a par value of $0.0001 per share. As of March 31, 2022 and December 31, 2021, there are no preference shares issued or outstanding.
Class A
Ordinary Shares-The Company is authorized to issue 380,000,000 Class A ordinary
shares with a par value of $0.0001 per share. As of March 31, 2022 and December 31, 2021, there were 28,090,000 Class A ordinary shares issued and outstanding, which were all subject to possible redemption and have been classified as temporary
equity (see Note 6).
Class F
Ordinary Shares-The Company is authorized to issue 50,000,000 Class F ordinary shares with a par value of $0.0001 per share. As of March 31, 2022 and December 31, 2021, the Company had 1,404,500 Class F ordinary shares issued and outstanding, which amounts have been adjusted to reflect the share exchange and share surrenders as discussed in Note 4.
The Class F ordinary shares will automatically convert into
Class A ordinary shares concurrently with or immediately following the consummation of the Partnering Transaction on a one-for-one
basis, subject to adjustment, for share splits, share dividends, reorganizations, recapitalizations and the like, and subject to further adjustment as provided herein. In the case that additional Class A ordinary shares or equity-linked
securities are issued or deemed issued in connection with the Partnering Transaction, the number of Class A ordinary shares issuable upon conversion of all Founder Shares will equal, in the aggregate, on an as-converted basis, 5% of the total number of as-converted Class A ordinary shares outstanding after such conversion (including the Forward Purchase Securities),
including the total number of Class A ordinary shares issued, or deemed issued or issuable upon conversion or exercise of any equity-linked securities or rights issued or deemed issued, by the Company in connection with or in relation to the
consummation of the Partnering Transaction; provided that such conversion of Founder Shares into Class A ordinary shares will never occur on a less than one-for-one basis.
15
For so long as any Class F ordinary shares remain
outstanding, the Company may not, without the prior vote or written consent of the holders of a majority of the Class F ordinary shares then outstanding, voting separately as a single class, amend, alter or repeal any provision of the Company’s
Amended and Restated Memorandum and Articles of Association, whether by merger, consolidation or otherwise, if such amendment, alteration or repeal would alter or change the powers, preferences or relative, participating, optional or other or
special rights of the Class F ordinary shares. Any action required or permitted to be taken at any meeting of the holders of Class F ordinary shares may be taken without a meeting, without prior notice and without a vote, if a consent or
consents in writing, setting forth the action so taken, shall be signed by the holders of the outstanding Class F ordinary shares having not less than the minimum number of votes that would be necessary to authorize or take such action at a
meeting at which all Class F ordinary shares were present and voted.
Class B
Ordinary Shares-The Company is authorized to issue 1,000,000 Class B ordinary shares with a par value of $0.0001 per share. As of March 31, 2022 and December 31, 2021, there were 250,000 Class B ordinary shares and issued and outstanding, which amounts have been adjusted to reflect the share exchange as discussed in Note 4.
On the last day of each fiscal year following the completion
of a Partnering Transaction (and, with respect to any year in which the Company has a change of control or in which the Company liquidates, dissolves or winds up, on the business day immediately prior to such event instead of on the last day of
such fiscal year), 25,000 Class B ordinary shares will automatically convert into Class A ordinary shares (“conversion shares”), as
follows:
• |
If the price per share of Class A ordinary shares
has not exceeded $10.00 for 20
out of 30 consecutive trading days at any time following completion of the Partnering Transaction, the number of conversion
shares for any fiscal year will be 2,500 Class A ordinary shares.
|
• |
If the price per share of Class A ordinary shares
exceeded $10.00 for 20
out of any 30 consecutive trading days at any time following completion of the Partnering Transaction, then the number of
conversion shares for any fiscal year will be the greater of:
|
o |
20% of the increase in the price of one Class A share, year-over-year but in respect of the increase above the relevant “price threshold” (as defined below),
multiplied by the number of Class A ordinary shares outstanding at the close of the Partnering Transaction, excluding those Class A ordinary shares received by the Sponsor through the Class F ordinary shares, divided by the annual
volume weighted average price of Class A ordinary shares for such fiscal year (the “annual VWAP”) and
|
o |
2,500 Class A ordinary shares.
|
• |
The increase in the price of Class A ordinary shares
will be based on the annual VWAP for the relevant fiscal year, it being understood that with respect to the 10th fiscal year following the Partnering Transaction the conversion calculation for the remaining 25,000 Performance Shares, the calculation described in the immediately preceding bullet will be based on the greater of (i) the annual VWAP
for such fiscal year and (ii) the volume-weighted average price of Class A ordinary shares over the last 20 trading days for
such fiscal year.
|
For purposes of the foregoing calculations, the “price
threshold” will initially equal $10.00 for the first fiscal year following completion of the Partnering Transaction and will
thereafter be adjusted at the beginning of each subsequent fiscal year to be equal to the greater of (i) the annual VWAP for the immediately preceding fiscal year and (ii) the price threshold for the preceding fiscal year.
For so long as any Class B ordinary shares remain
outstanding, including prior to the Partnering Transaction, in connection with the Partnering Transaction, or following the Partnering Transaction, the Company may not, without the prior vote or written consent of the holders of a majority of
the Performance Shares then outstanding, voting separately as a single class, (A) amend, alter or repeal any provision in the Company’s Amended and Restated Memorandum and Articles of Association, whether by merger, consolidation or otherwise,
if such amendment, alteration or repeal would alter or change the powers, preferences or relative, participating, optional or other or special rights of the Class B ordinary shares, (B) change the Company’s fiscal year, (C) increase the number
of directors on the board, (D) pay any dividends or effect any split on any of the Company’s capital stock, (E) adopt any shareholder rights plan, (F) acquire any entity or business with assets at a purchase price greater than 10% or more of the Company’s total assets or (G) issue any Class A ordinary shares in excess of 20% of the Company’s then outstanding Class A ordinary shares or that would otherwise require a shareholder vote pursuant to the rules of the stock exchange on which the
Class A ordinary shares are then listed.
16
NOTE
8. WARRANTS
In connection with the Initial Public Offering and over-allotment, 9,363,333
Public Warrants and 5,412,000 Private Placement Warrants were issued as of March 31, 2022 and December 31, 2021.
No fractional warrants will be issued upon separation of the units and only whole warrants will trade. Each whole warrant entitles the registered holder to purchase one share of Class A ordinary shares at a price of $11.50
per share, subject to adjustment, as discussed below, at any time commencing 30 days after the completion of a Partnering
Transaction, provided in each case that the Company has an effective registration statement under the Securities Act covering the Class A ordinary shares issuable upon exercise of the warrants and a current prospectus relating to them is
available (or the Company permits holders to exercise their warrants on a cashless basis under the circumstances specified in the warrant agreement) and such shares are registered, qualified or exempt from registration under the securities, or
blue sky, laws of the state of residence of the holder. The Company has agreed that as soon as practicable, but in no event later than fifteen (15)
business days after the closing of the Partnering Transaction, the Company will use its commercially reasonable efforts to file with the SEC a registration statement, under the Securities Act, of the Class A ordinary shares issuable upon
exercise of the warrants. The Company will use its commercially reasonable efforts to cause the same to become effective and to maintain the effectiveness of such registration statement, and a current prospectus relating thereto, until the
expiration of the warrants in accordance with the provisions of the warrant agreement. If a registration statement covering the Class A ordinary shares issuable upon exercise of the warrants is not effective by the sixtieth (60th) business day after the closing of the Partnering Transaction, warrant holders may, until such time as there is an effective registration
statement and during any period when the Company will have failed to maintain an effective registration statement, exercise warrants on a “cashless basis” in accordance with Section 3(a)(9) of the Securities Act or another exemption.
Notwithstanding the above, if the Class A ordinary shares are at the time of any exercise of a warrant not listed on a national securities exchange such that they satisfy the definition of a “covered security” under Section 18(b)(1) of the
Securities Act, the Company may, at its option, require holders of Public Warrants who exercise their warrants to do so on a “cashless basis” in accordance with Section 3(a)(9) of the Securities Act and, in the event the Company so elects, it
will not be required to file or maintain in effect a registration statement, and in the event the Company does not so elect, it will use its commercially reasonable efforts to register or qualify the shares under applicable blue sky laws to the
extent an exemption is not available.
The warrants will expire five years after the completion of the Partnering Transaction, or earlier upon redemption or liquidation. In addition, if (x) the Company issues
additional Class A ordinary shares or equity-linked securities for capital raising purposes in connection with the Partnering Transaction, including the Forward Purchase Shares, at an issue price or effective issue price of less than $9.20 per share of Class A ordinary shares (with such issue price or effective issue price to be determined in good faith by the board of directors
and, in the case of any such issuance to the Sponsor or its affiliates, without taking into account any shares held by the Sponsor or such affiliates, as applicable, prior to such issuance) (the “Newly Issued Price”), (y) the aggregate gross
proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding
of the Partnering Transaction on the date of the consummation of the Partnering Transaction (net of redemptions), and (z) the volume weighted average trading price of the Class A ordinary shares during the 20 trading day period starting on the trading day after the day on which the Company consummates the Partnering Transaction (such price, the “Market
Value”) is below $9.20 per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to 110% of the higher of the Market Value and the $15.00
redemption price trigger described below will be equal to 180% of the higher of the Market Value and the Newly Issued Price.
The Private Placement Warrants are identical to the Public
Warrants, except that the Private Placement Warrants and the Class A ordinary shares issuable upon exercise of the Private Placement Warrants will not be transferable, assignable or salable until 30 days after the completion of a Partnering Transaction, subject to certain limited exceptions. Additionally, the Private Placement Warrants will be non-redeemable so long
as they are held by the Sponsor or its permitted transferees. If the Private Placement Warrants are held by someone other than the Sponsor or its permitted transferees, the Private Placement Warrants will be redeemable by the Company and
exercisable by such holders on the same basis as the Public Warrants.
17
The Company may also redeem the Public Warrants, in whole and not in part, at a price of $0.01 per warrant:
• |
at any time while the warrants are exercisable,
|
• |
upon a minimum of 30 days’ prior written notice of redemption,
|
• |
if, and only if, the last sales price of the Class A
ordinary shares equals or exceeds $15.00 per share for any 20 trading days within a 30 trading day period (the “30-day trading period”) ending
business days before the Company sends the notice of redemption, and |
• |
if, and only if, there is a current registration
statement in effect with respect to the Class A ordinary shares underlying such warrants commencing
business days prior
to the 30-day trading period and continuing each day thereafter until the date of redemption. |
If the Company calls the Public Warrants for redemption,
management will have the option to require all holders that wish to exercise the Public Warrants to do so on a “cashless basis,” as described in the warrant agreement.
In no event will the Company be required to net cash settle
any warrant. If the Company is unable to complete a Partnering Transaction within the Partnering Period and the Company liquidates the funds held in the Trust Account, holders of warrants will not receive any of such funds with respect to their
warrants, nor will they receive any distribution from the Company’s assets held outside of the Trust Account with the respect to such warrants. Accordingly, the warrants may expire worthless.
NOTE 9. FAIR VALUE MEASUREMENTS
The following table presents information about the Company’s financial assets and liabilities that are measured at fair value on a recurring basis as of March 31, 2022
and December 31, 2021, by level within the fair value hierarchy:
March 31, 2022
Description |
Quoted Prices in Active
Markets
(Level 1)
|
Significant Other
Observable Inputs
(Level 2)
|
Significant Other
Unobservable Inputs
(Level 3)
|
|||||||||
Assets:
|
||||||||||||
Investments held in Trust Account - U.S. Treasury Securities
|
$ |
281,016,296 |
$ |
- | $ |
- | ||||||
Liabilities:
|
||||||||||||
Derivative warrant liabilities - Public warrants |
$ |
3,932,600 |
$ |
- |
$ |
- |
||||||
Derivative warrant liabilities - Private placement warrants
|
$ |
- |
$ |
- |
$ |
2,273,040 |
December 31, 2021
Description
|
Quoted Prices in Active
Markets
(Level 1)
|
Significant Other
Observable Inputs
(Level 2)
|
Significant Other
Unobservable Inputs
(Level 3)
|
|||||||||
Assets:
|
||||||||||||
Investments held in Trust Account - U.S. Treasury Securities
|
$
|
280,950,832
|
$
|
-
|
$
|
-
|
||||||
Liabilities:
|
||||||||||||
Derivative warrant liabilities - Public warrants
|
$
|
9,456,966
|
$
|
-
|
$
|
-
|
||||||
Derivative warrant liabilities - Private placement warrants
|
$
|
-
|
$
|
-
|
$
|
5,520,240
|
Transfers to/from Levels 1, 2 and 3 are recognized at the beginning of the reporting period. The estimated fair value of the Public Warrants was transferred from a Level 3 measurement to a Level 1 measurement, when the Public Warrants were separately listed and traded in August 2021. There were no other transfers to/from Levels 1,2, and 3 during the three months ended March 31, 2022.
Level 1 assets and liabilities include investments in U.S. government securities and derivative warrant liabilities (Public Warrants), respectively. The Company uses
inputs such as actual trade data, benchmark yields, quoted market prices from dealers or brokers, and other similar sources to determine the fair value of its investments.
18
For periods where no observable traded price is available, the fair value of the Public Warrants has been estimated using a Monte Carlo simulation and of the
Private Placement Warrants has been estimated using a Black-Scholes option pricing model. For periods subsequent to the detachment of the Public Warrants from the Units, the fair value of the Public Warrants is based on the observable listed
price for such warrants. For the three months ended March 31, 2022 and for the period from January 1, 2021 (commencement of operations) through March 31, 2021, the Company recognized gain/(loss) on the unaudited condensed statements of
operations resulting from a decrease/(increase) in the fair value of liabilities of approximately $8.8 million and $0, respectively presented as change in fair value of derivative warrant liabilities on the accompanying unaudited condensed statements of
operations.
The estimated fair value of the Public and Private Placement Warrants, prior to the Public Warrants being traded in an active market, was determined using Level 3
inputs. Inherent in a Monte Carlo simulation and a Black-Scholes option pricing model are assumptions related to expected stock-price volatility, expected life, risk-free interest rate and dividend yield. The Company estimates the volatility of
its warrants based on implied volatility from the Company’s traded warrants and from historical volatility of select peer companies ordinary shares that match the expected remaining life of the warrants. The risk-free interest rate is based on
the U.S. Treasury zero-coupon yield curve on the grant date for a maturity similar to the expected remaining life of the warrants. The expected life of the warrants is assumed to be equivalent to their remaining contractual term. The dividend
rate is based on the historical rate, which the Company anticipates remaining at zero.
The following table provides quantitative information regarding Level 3 fair value measurements input at their measurement dates:
As of March 31, 2022 |
As of December 31, 2021 |
|||||||
Exercise price
|
$ | 11.50 | $ | 11.50 | ||||
Stock price
|
$ | 9.71 | $ | 9.76 | ||||
Volatility |
6.3
|
%
|
15.2
|
%
|
||||
Term (years) |
5.5 | 5.5 | ||||||
Risk-free rate
|
2.40 | % | 1.30 | % | ||||
Dividend yield |
0.0
|
%
|
0.0
|
%
|
The change in the fair value of the derivative liabilities, measured using Level 3 inputs, for the three months ended March 31, 2022, is summarized as follows:
Derivative warrant liabilities at December 31, 2021 | $ |
5,520,240 | ||
Change in fair value of derivative warrant liabilities
|
(3,247,200 | ) | ||
Derivative warrant liabilities at March 31, 2022 | $ |
2,273,040 |
NOTE
10. SUBSEQUENT EVENTS
The Company evaluated subsequent events and transactions that occurred up to the date unaudited condensed financial statements were issued. Based upon this review,
the Company did not identify any subsequent events that would have required adjustment or disclosure in the unaudited condensed financial statements, which have not previously been disclosed within the unaudited condensed financial statements.
Item 2. |
Management’s Discussion and Analysis of Financial Condition and Results of Operations.
|
References to the “Company,” “Corsair Partnering Corporation,” “Corsair,” “our,” “us” or “we” refer to Corsair Partnering Corporation. The
following discussion and analysis of the Company’s financial condition and results of operations should be read in conjunction with the financial statements and the notes thereto contained elsewhere in this report. Certain information contained
in the discussion and analysis set forth below includes forward-looking statements that involve risks and uncertainties.
Cautionary Note Regarding Forward-Looking Statements
This Quarterly Report on Form 10-Q includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Exchange Act. We have based these forward-looking statements on our current expectations and projections about future events. These forward-looking statements are subject to known and unknown risks, uncertainties
and assumptions about us that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by such
forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “should,” “could,” “would,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “continue,” or the negative of such terms or
other similar expressions. Factors that might cause or contribute to such a discrepancy include, but are not limited to, those described in our other SEC filings.
Overview
Corsair Partnering Corporation (the “Company”) was incorporated as a Cayman Islands exempted company on December 29, 2020. The Company was formed for the purpose
of identifying a company to partner with, in order to effectuate a merger, share exchange, asset acquisition, share purchase, reorganization or similar Partnering Transaction with one or more businesses (“Partnering Transaction”). The Company may
pursue a Partnering Transaction in any business or industry but expect to focus on a business where the Company believes its strong network, operational background, and aligned economic structure will provide the Company with a competitive
advantage. The Company has not generated revenue to date.
The Company’s management has broad discretion with respect to the specific application of the net proceeds of its initial public offering (the “Initial Public
Offering”) as it is described below, although substantially all of the net proceeds of the Initial Public Offering are intended to be generally applied toward completing a Partnering Transaction. Furthermore, there is no assurance that the
Company will be able to successfully complete a Partnering Transaction.
The registration statement for the Company’s Initial Public Offering was declared effective on June 30, 2021. On July 6, 2021, the Company consummated its
Initial Public Offering of 25,000,000 units (the “Units” and, with respect to the Class A Ordinary Shares included in the Units being offered, the “Public Shares”), at $10.00 per Unit, generating gross proceeds of $250.0 million, and incurring
offering costs of approximately $14.4 million, of which approximately $8.8 million and approximately $481,000 was for deferred underwriting commissions and offering costs allocated to derivate warrant liabilities, respectively. On July 15, 2021,
the underwriters purchased an additional 3,090,000 Units (the “Option Units”) pursuant to the partial exercise of the over-allotment option. The Option Units were sold at an offering price of $10.00 per Unit, generating additional gross proceeds
to the Company of $30.9 million. The Company incurred additional offering cost of approximately $1.7 million in connection with the over-allotment, of which approximately $1.1 million was for deferred underwriting commissions and approximately
$55,000 was offering costs allocated to derivative warrant liabilities.
Simultaneously with the closing of the Initial Public Offering, the Company consummated the private placement (“Private Placement”) of 5,000,000 warrants (each,
a “Private Placement Warrant” and collectively, the “Private Placement Warrants”) at a price of $1.50 per Private Placement Warrant to the Sponsor, generating proceeds of $7.5 million). In connection with the exercise of the over-allotment option
on July 15, 2021, the Sponsor purchased an additional 412,000 Private Placement Warrants at a purchase price of $1.50 per Private Placement Warrant, generating additional gross proceeds to the Company of $618,000.
Following the closing of the Initial Public Offering and the Private Placement, $280.9 million ($10.00 per Unit, and including $30,900,000 in connection with the
underwriters’ partial exercise of the over-allotment option) of the net proceeds of the sale of the Units in the Initial Public Offering and of the Private Placement Warrants in the Private Placement were placed in a trust account (“Trust
Account”), located in the United States and will be invested only in United States “government securities” within the meaning of Section 2(a)(16) of the Investment Company Act of 1940, as amended (the “Investment Company Act”) having a maturity
of 185 days or less or in money market funds meeting certain conditions under Rule 2a-7 promulgated under the Investment Company Act which invest only in direct U.S. government treasury obligations, until the earlier of: (i) the completion of a
Partnering Transaction and (ii) the distribution of the Trust Account as described below.
The Company must complete a Partnering Transaction with one or more partner candidate businesses having an aggregate fair market value of at least 80% of the net
assets held in the Trust Account (excluding the taxes payable on the income earned on the Trust Account) at the time of the agreement to enter into the initial Partnering Transaction. However, the Company will only complete a Partnering
Transaction if the post-transaction company owns or acquires 50% or more of the voting securities of the partner candidate or otherwise acquires a controlling interest in the partner candidate sufficient for it not to be required to register as
an investment company under the Investment Company Act.
The Company’s Amended and Restated Memorandum and Articles of Association provides that, other than the withdrawal of interest earned on the funds that may be
released to the Company for withdrawals to pay taxes including income and franchise taxes and to withdraw up to $100,000 in dissolution expenses in the event the Company does not complete the Partnering Transaction within the Partnering Period
(as defined below), none of the funds held in the Trust Account will be released until the earlier of: (i) the completion of the Partnering Transaction; (ii) the redemption of any of the Public Shares by its holders (the “Public Shareholders”)
properly tendering Public Shares in connection with a shareholder vote to amend certain provisions of the Company’s Amended and Restated Memorandum and Articles of Association prior to a Partnering Transaction or (iii) the redemption of 100% of
the Public Shares if the Company does not complete a Partnering Transaction within the Partnering Period (defined below).
The Company, after signing a definitive agreement for a Partnering Transaction, will either (i) seek shareholder approval of the Partnering Transaction at a
meeting called for such purpose in connection with which Public Shareholders may seek to redeem their Public Shares, regardless of whether they vote for or against the Partnering Transaction or do not vote at all, for cash equal to their pro rata
share of the aggregate amount then on deposit in the Trust Account calculated as of two business days prior to the consummation of the initial Partnering Transaction, including interest earned on the funds held in the Trust Account and not
previously released to the Company to pay its taxes, or (ii) provide the Public Shareholders with the opportunity to sell their shares to the Company by means of a tender offer (and thereby avoid the need for a shareholder vote) for an amount in
cash equal to their pro rata share of the aggregate amount then on deposit in the Trust Account calculated as of two business days prior to commencement of the tender offer, including interest earned on the funds held in the Trust Account and not
previously released to the Company to pay its taxes. As a result, such Ordinary Shares subject to possible redemption were recorded at redemption amount and classified as temporary equity, in accordance with FASB, ASC 480, “Distinguishing
Liabilities from Equity.” The amount in the Trust Account was initially at $10.00 per Public Share. The decision as to whether the Company will seek shareholder approval of the Partnering Transaction or will allow shareholders to sell their
shares in a tender offer will be made by the Company, solely in its discretion, and will be based on a variety of factors such as the timing of the transaction and whether the terms of the transaction would otherwise require the Company to seek
shareholder approval. If the Company seeks shareholder approval, it will complete its Partnering Transaction only if a majority of the outstanding Ordinary Shares voted are voted in favor of the Partnering Transaction. However, in no event will
the Company redeem its Public Shares in an amount that would cause its net tangible assets to be less than $5,000,001 immediately prior to or upon consummation of the Company’s initial Partnering Transaction. In such case, the Company would not
proceed with the redemption of its Public Shares and the related Partnering Transaction, and instead may search for an alternate Partnering Transaction.
The Company will only have at most until October 6, 2023 to complete its initial Partnering Transaction (the “Partnering Period”). If the Company does not
complete a Partnering Transaction within this period of time (and shareholders do not approve an amendment to the Amended and Restated Memorandum and Articles of Association to extend this date), it will (i) cease all operations except for the
purpose of winding up, (ii) as promptly as reasonably possible but not more than ten business days thereafter, redeem the Public Shares, at a per-share price, payable in cash, of $10.00, and (iii) as promptly as reasonably possible following such
redemption, subject to the approval of our remaining shareholders and our board of directors, liquidate and dissolve, subject in the case of clauses (ii) and (iii), to our obligations under Cayman Islands law to provide for claims of creditors
and in all cases subject to the other requirements of applicable law.
The holders of the Founder Shares immediately prior to the Initial Public Offering entered into a Letter Agreement with the Company, pursuant to which they
agreed to (i) waive their redemption rights with respect to any Founder Shares and Public Shares they hold in connection with the completion of the Partnering Transaction, (ii) waive their redemption rights with respect to any Founder Shares and
Public Shares they hold in connection with a shareholder vote to approve an amendment to the Company’s Amended and Restated Memorandum and Articles of Association, to modify the substance or timing of the Company’s obligation to redeem 100% of
its Public Shares if the Company has not consummated a Partnering Transaction within the Partnering Period or with respect to any other material provisions relating to shareholders’ rights or pre-Partnering Transaction activity and (iii) waive
their rights to liquidating distributions from the Trust Account with respect to any Founder Shares they hold if the Company fails to complete the Partnering Transaction within 24 months of the Partnering Period (although they will be entitled to
liquidating distributions from the Trust Account with respect to any Public Shares they hold if the Company fails to complete the Partnering Transaction within the Partnering Period).
Pursuant to the Letter Agreement, the Sponsor agreed that it will be liable to the Company if and to the extent any claims by a third party for services rendered
or products sold to the Company, or a prospective target business with which the Company has entered into a written letter of intent, confidentiality or other similar agreement or Partnering Transaction agreement, reduce the amount of funds in
the Trust Account to below the lesser of (i) $10.00 per Public Share and (ii) the actual amount per Public Share held in the Trust Account as of the date of the liquidation of the Trust Account, if less than $10.00 per Public Share due to
reductions in the value of the Trust assets, less taxes payable, provided that such liability will not apply to any claims by a third party or prospective target business who executed a waiver of any and all rights to the monies held in the Trust
Account (whether or not such waiver is enforceable) nor will it apply to any claims under the Company’s indemnity of the underwriters of the Initial Public Offering against certain liabilities, including liabilities under the Securities Act.
Prior to the Partnering Transaction or the liquidation, the Company agreed to pay the Sponsor up to $15,000 per month for office space, administrative support
and other services provided to members of the Company’s management team. In addition, the Sponsor, officers and directors, or any of their respective affiliates will be reimbursed for any out-of-pocket expenses incurred in connection with
activities on the Company’s behalf such as identifying potential target businesses and performing due diligence on suitable Partnering Transactions. The audit committee will review on a quarterly basis all payments that were made by the Company
to the Sponsor, officers or directors, or the Company’s or their affiliates. Any such payments prior to an initial Partnering Transaction will be made from funds held outside the Trust Account. As of March 31, 2022 and December 31, 2021, the
Company had a receivable of approximately $9,000 and a payable of $2,000, respectively, in due to related party for such expense reimbursement.
Liquidity and Capital Resources
As of March 31, 2022, the Company had approximately $537,000 in its operating bank account and working capital of approximately $713,000.
The Company’s liquidity needs prior to the consummation of the Initial Public Offering were satisfied through the payment of $25,000 from related parties to
cover for certain expenses on the Company’s behalf in exchange for issuance of Founder Shares and Performance Shares, a loan from the Sponsor under the Note of approximately $231,000, and an advance from the Sponsor of $750,000 to be used in case
the over-allotment option was exercised in full by the underwriters. The Company repaid the Note balance of approximately $231,000 on July 6, 2021. Subsequent to the consummation of the Initial Public Offering, the Company’s liquidity has been
satisfied through the net proceeds from the consummation of the Initial Public Offering and the Private Placement held outside of the Trust Account. In addition, in order to finance transaction costs in connection with a Partnering Transaction,
the Sponsor or an affiliate of the Sponsor, or certain of the Company’s officers and directors may, but are not obligated to, provide the Company working capital loans. As of March 31, 2022 and December 31, 2021, there were no amounts outstanding
under any working capital loan.
Based on the foregoing, management believes that the Company will have sufficient working capital and borrowing capacity to meet its needs through the earlier of
the consummation of a Partnering Transaction or one year from this filing. Over this time period, the Company will be using the funds held outside of the Trust Account for paying existing accounts payable, identifying and evaluating prospective
initial Partnering Transaction candidates, performing due diligence on prospective target businesses, paying for travel expenditures, selecting the target business to merge with or acquire, and structuring, negotiating and consummating the
Partnering Transaction.
Results of Operations
Our entire activity from January 1, 2021 (commencement of operations) through March 31, 2022 was in preparation for our formation and the Initial Public
Offering, and since the Initial Public Offering, our search for a Partnering Transaction. We will not be generating any operating revenues until the closing and completion of our initial Partnering Transaction.
For the three months ended March 31, 2022, we had net gain of approximately $8,406,000 dollars, which consisted of a non-cash gain of approximately $8,772,000
for the change in fair value of derivative warrant liabilities, approximately $65,000 of income from investments held in the Trust Account, offset by approximately $431,000 of general and administrative expenses.
For the period from January 1, 2021 (commencement of operations) through March 31, 2021, we had net loss of approximately $34,000, which consisted of general and
administrative expenses.
Contractual Obligations
Forward Purchase Agreement
On June 30, 2021, the Company entered into a Forward Purchase Agreement with an affiliate, Corsair V Financial Services Capital Partners L.P. (the “Forward
Purchaser”), pursuant to which the Forward Purchaser agreed to purchase in the aggregate, up to 10,000,000 Units, with each Unit consisting of one Class A ordinary share and one-third of one warrant to purchase one Class A ordinary share at
$11.50 per share, subject to adjustment, at a purchase price of $10.00 per Unit, in private placements to occur concurrently, and only in connection with, the closing of the initial Partnering Transaction. The obligations of the Forward Purchaser
under the Forward Purchase Agreement will not depend on whether any Class A Ordinary Shares are redeemed by the Public Shareholders. The obligations of the Forward Purchaser to purchase the Forward Purchase Securities are subject to the approval,
prior to the Company entering into a definitive agreement for the initial Partnering Transaction, of its investment committee and the Forward Purchase Agreement contains customary closing conditions. The Forward Purchase Agreement is not a firm
commitment by either party to the agreement. The proceeds from the sale of Forward Purchase Securities, if any, may be used as part of the consideration to the sellers in the initial Partnering Transaction, expenses in connection with the initial
Partnering Transaction or for working capital in the post-transaction company.
Registration Rights
The holders of the Founder Shares, Performance Shares, Forward Purchase Securities, Private Placement Warrants and Private Placement Warrants that may be issued
upon conversion of working capital loans (and any Class A Ordinary Shares issuable upon the exercise of the Private Placement Warrants, and Private Placement Warrants that may be issued upon conversion of working capital loans and upon conversion
of the Founder Shares and the Performance Shares) were entitled to registration rights pursuant to a registration rights agreement signed upon the effective date of the Initial Public Offering, requiring the Company to register such securities
for resale. The holders of these securities are entitled to make up to three demands, excluding short form demands, that the Company registers such securities. In addition, the holders have certain “piggy-back” registration rights with respect to
registration statements filed subsequent to the completion of the Partnering Transaction. The Company will bear the expenses incurred in connection with the filing of any such registration statements.
Pursuant to the Forward Purchase Agreement, in the event of a sale, if any, of the Forward Purchase Securities, the Company expects to agree to use its
reasonable best efforts (i) to file within 30 days after the closing of the initial Partnering Transaction a registration statement with the SEC for a secondary offering of the Forward Purchase Shares and the Forward Purchase Warrants (and
underlying Class A Ordinary Shares), (ii) to cause such registration statement to be declared effective promptly thereafter but in no event later than 60 days after the initial filing, (iii) to maintain the effectiveness of such registration
statement until the earliest of (A) the date on which the Forward Purchasers or its assignees cease to hold the securities covered thereby and (B) the date all of the securities covered thereby can be sold publicly without restriction or
limitation under Rule 144 under the Securities Act and (iv) after such registration statement is declared effective, to cause the Company to conduct firm commitment underwritten offerings, subject to certain limitations. In addition, the Forward
Purchase Agreement provides for certain “piggy-back” registration rights to the holders of Forward Purchase Securities to include their securities in other registration statements filed by the Company.
Underwriting Agreement
The Company granted the underwriters a 45-day option from the date of the final prospectus relating to the Initial Public Offering to purchase up to 3,750,000
additional Units to cover over-allotments, if any, at the Initial Public Offering price less the underwriting discounts and commissions. On July 15, 2021, the underwriters purchased an additional 3,090,000 Option Units pursuant to the partial
exercise of the over-allotment option. The Option Units were sold at an offering price of $10.00 per Unit, generating additional gross proceeds to the Company of $30,900,000. Except for the 1,000,000 Units purchased by certain parties in the
Initial Public Offering, the underwriters were entitled to an underwriting discount of $0.20 per unit, or $5.4 million in the aggregate, paid upon the closing of the Initial Public Offering and exercise of the over-allotment option.
In addition, $0.35 per unit, or approximately $9.8 million in the aggregate, will be payable to the underwriters for deferred underwriting commissions. The
deferred fee will become payable to the underwriters from the amounts held in the Trust Account solely in the event that the Company completes a Partnering Transaction, subject to the terms of the underwriting agreement.
Critical Accounting Policies and Estimates
This management’s discussion and analysis of our financial condition and results of operations is based on our condensed financial statements, which have been
prepared in accordance with U.S. GAAP. The preparation of these condensed financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses and the disclosure of
contingent assets and liabilities in our condensed financial statements. On an ongoing basis, we evaluate our estimates and judgments, including those related to fair value of financial instruments and accrued expenses. We base our estimates on
historical experience, known trends and events and various other factors that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that
are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. We have identified the following as our critical accounting policies:
Derivative Warrant Liabilities
We do not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. We evaluate all of our financial instruments, including
issued share purchase warrants, to determine if such instruments are derivatives or contain features that qualify as embedded derivatives, pursuant to ASC 480 and FASB ASC Topic 815, “Derivatives and Hedging” (“ASC 815”). The classification of
derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period.
The Public Warrants and the Private Placement Warrants are recognized as derivative liabilities in accordance with ASC 815. Accordingly, we recognize the warrant
instruments as liabilities at fair value and adjusts the carrying value of the instruments to fair value at each reporting period until they are exercised. The initial fair value of the Public Warrants issued in connection with the Initial Public
Offering were estimated using a Monte-Carlo simulation model. The fair value of the Public Warrants as of March 31, 2022 and December 31, 2021 is based on observable listed prices for such warrants. The fair value of the Private Placement
Warrants as of March 31, 2022 and December 31, 2021 is determined using Black-Scholes option pricing model. The determination of the fair value of the warrant liability may be subject to change as more current information becomes available and
accordingly the actual results could differ significantly. Derivative warrant liabilities are classified as non-current liabilities as their liquidation is not reasonably expected to require the use of current assets or require the creation of
current liabilities.
Class A Ordinary Shares Subject to Possible Redemption
We account for our Class A Ordinary Shares subject to possible redemption in accordance with the guidance in ASC Topic 480 “Distinguishing Liabilities from
Equity.” Class A Ordinary Shares subject to mandatory redemption (if any) are classified as liability instruments and are measured at fair value. Conditionally redeemable Class A Ordinary Shares (including Class A Ordinary Shares that feature
redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within our control) are classified as temporary equity. At all other times, Class A Ordinary Shares is
classified as shareholders’ equity. Our Class A Ordinary Shares feature certain redemption rights that are considered to be outside of our control and subject to the occurrence of uncertain future events. Accordingly, as of March 31, 2022 and
December 31, 2021, 28,090,000 Class A Ordinary Shares subject to possible redemption are presented at redemption value as temporary equity, outside of the shareholders’ deficit section of our condensed balance sheets.
Under ASC 480-10-S99, we have elected to recognize changes in the redemption value immediately as they occur and adjust the carrying value of the security to
equal the redemption value at the end of the reporting period. This method would view the end of the reporting period as if it were also the redemption date of the security. Effective with the closing of the Initial Public Offering (including
exercise of the over-allotment option), we recognized the accretion from initial book value to redemption amount, which resulted in charges against additional paid-in capital (to the extent available) and accumulated deficit.
Net Income (Loss) Per Ordinary Share
We comply with accounting and disclosure requirements of FASB ASC Topic 260, “Earnings Per Share.” We have three classes of shares, which are referred to as
Class A Ordinary Shares, Class B Ordinary Shares, and Class F Ordinary Shares. Income and losses are shared pro rata between the three classes of shares. This presentation assumes a business combination as the most likely outcome. Net income
(loss) per ordinary share is calculated by dividing the net income (loss) by the weighted average shares of Ordinary Shares outstanding for the respective period.
The calculation of diluted net income (loss) per ordinary share does not consider the effect of the warrants issued in connection with the Initial Public
Offering (including exercise of the over-allotment option) and the Private Placement to purchase an aggregate of 14,775,333 Class A Ordinary Shares in the calculation of diluted income (loss) per ordinary share, because their exercise is
contingent upon future events and their inclusion would be anti-dilutive under the treasury stock method. As a result, diluted net income (loss) per ordinary share is the same as basic net income (loss) per share for the three months ended March
31, 2022 and for the period from January 1, 2021 (commencement of operations) through March 31, 2021. Accretion associated with the redeemable Class A Ordinary Shares is excluded from earnings per share as the redemption value approximates fair
value.
Recent Accounting Pronouncements
Management does not believe that any recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the
Company’s condensed financial statements.
Off-Balance Sheet Arrangements
As of March 31, 2022, we did not have any off-balance sheet arrangements as defined in Item 303(a)(4)(ii) of Regulation S-K and did not have any commitments or
contractual obligations.
JOBS Act
On April 5, 2012, the JOBS Act was signed into law. The JOBS Act contains provisions that, among other things, relax certain reporting requirements for
qualifying public companies. We qualify as an “emerging growth company” and under the JOBS Act are allowed to comply with new or revised accounting pronouncements based on the effective date for private (not publicly traded) companies. We are
electing to delay the adoption of new or revised accounting standards, and as a result, we may not comply with new or revised accounting standards on the relevant dates on which adoption of such standards is required for non-emerging growth
companies. As such, our condensed financial statements may not be comparable to companies that comply with public company effective dates.
Additionally, we are in the process of evaluating the benefits of relying on the other reduced reporting requirements provided by the JOBS Act. Subject to
certain conditions set forth in the JOBS Act, if, as an “emerging growth company,” we choose to rely on such exemptions we may not be required to, among other things, (i) provide an auditor’s attestation report on our system of internal controls
over financial reporting pursuant to Section 404, (ii) provide all of the compensation disclosure that may be required of non-emerging growth public companies under the Dodd-Frank Wall Street Reform and Consumer Protection Act, (iii) comply with
any requirement that may be adopted by the PCAOB regarding mandatory audit firm rotation or a supplement to the auditor’s report providing additional information about the audit and the financial statements (auditor discussion and analysis) and
(iv) disclose certain executive compensation related items such as the correlation between executive compensation and performance and comparisons of the CEO’s compensation to median employee compensation. These exemptions will apply for a period
of five years following the completion of our Initial Public Offering or until we are no longer an “emerging growth company,” whichever is earlier.
Item 3. |
Quantitative and Qualitative Disclosures About Market Risk
|
We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information otherwise required under this
item.
Item 4. |
Controls and Procedures
|
Evaluation of Disclosure Controls and Procedures
Under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, we conducted an
evaluation of the effectiveness of our disclosure controls and procedures as of the end of the fiscal quarter ended March 31, 2022, as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act. Based on this evaluation, our
principal executive officer and principal financial officer have concluded that during the period covered by this Report, our disclosure controls and procedures were not effective as of March 31, 2022, because of a material weakness in our
internal control over financial reporting. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the
Company’s annual or interim financial statements will not be prevented or detected on a timely basis. Specifically, the Company’s management has concluded that our control around the interpretation and accounting for certain complex equity
instruments issued by the Company was not effectively designed or maintained. This material weakness resulted in the restatement of the Company’s condensed balance sheet as of July 6, 2021. Additionally, this material weakness could result in a
misstatement of the carrying value of equity, equity-linked instruments and related accounts and disclosures that would result in a material misstatement of the financial statements that would not be prevented or detected on a timely basis. As a
result, our management performed additional analysis as deemed necessary to ensure that our financial statements were prepared in accordance with generally accepted in the United States of America. Accordingly, management believes that the
financial statements included in this Form 10-Q present fairly, in all material respects, our financial position, result of operations and cash flows of the period presented. Management understands that the accounting standards applicable to our
financial statements are complex and has since the inception of the Company benefited from the support of experienced third-party professionals with whom management has regularly consulted with respect to accounting issues. Management intends to
continue to further consult with such professionals in connection with accounting matters.
Disclosure controls and procedures are designed to ensure that information required to be disclosed by us in our Exchange Act reports is recorded, processed,
summarized, and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer or
persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.
Changes in Internal Control over Financial Reporting
There was no change in our internal control over financial reporting that occurred during the fiscal quarter ended March 31, 2022, covered by this Quarterly
Report on Form 10-Q that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
Our principal executive officer and principal financial officer performed additional accounting and financial analyses and other post-closing procedures
including consulting with subject matter experts related to the accounting for certain complex equity instruments. The Company’s management has expended, and will continue to expend, a substantial amount of effort and resources for the
remediation and improvement of our internal control over financial reporting. While we have processes to properly identify and evaluate the appropriate accounting technical pronouncements and other literature for all significant or unusual
transactions, we have expanded and will continue to improve these processes to ensure that the nuances of such transactions are effectively evaluated in the context of the increasingly complex accounting standards.
PART II - OTHER INFORMATION
Item 1. |
Legal Proceedings
|
None.
Item 1A. |
Risk Factors
|
As of the date of this Quarterly Report on Form 10-Q, there have been no material changes to the risk factors disclosed in our Form 10-K filed with the SEC on March 29, 2022. We may
disclose changes to such factors or disclose additional factors from time to time in our future filings with the SEC.
Item 2. |
Unregistered Sales of Equity Securities and Use of Proceeds from Registered Securities
|
There has been no material change in the planned use of the proceeds from the Initial Public Offering and the Private Placement as is described in our final
prospectus related to the Initial Public Offering.
Item 3. |
Defaults upon Senior Securities
|
None.
Item 4. |
Mine Safety Disclosures.
|
Not applicable.
Item 5. |
Other Information.
|
None.
Item 6. |
Exhibits.
|
Exhibit
Number
|
Description
|
Certification of Chief Executive Officer (Principal Executive Officer) Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of
1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
|
|
Certification of Chief Financial Officer (Principal Financial and Accounting Officer) Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities
Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
|
|
Certification of Chief Executive Officer (Principal Executive Officer) Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002.
|
|
Certification of Chief Financial Officer (Principal Financial and Accounting Officer) Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section
906 of the Sarbanes-Oxley Act of 2002.
|
|
101.INS*
|
XBRL Instance Document
|
101.SCH*
|
XBRL Taxonomy Extension Schema Document
|
101.CAL*
|
XBRL Taxonomy Extension Calculation Linkbase Document
|
101.DEF*
|
XBRL Taxonomy Extension Definition Linkbase Document
|
101.LAB*
|
XBRL Taxonomy Extension Label Linkbase Document
|
101.PRE*
|
XBRL Taxonomy Extension Presentation Linkbase Document
|
* |
Filed herewith.
|
** |
These certifications are furnished to the SEC pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and are deemed not filed for purposes of Section
18 of the Securities Exchange Act of 1934, as amended, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth by specific reference in such filing.
|
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
Dated: May 13, 2022
|
CORSAIR PARTNERING CORPORATION
|
|
By:
|
/s/ D.T Ignacio Jayanti
|
|
Name:
|
D.T Ignacio Jayanti
|
|
Title:
|
Chief Executive Officer
(Principal Executive Officer)
|
|
Dated: May 13, 2022
|
||
By:
|
/s/ Paul Cabral
|
|
Name:
|
Paul Cabral
|
|
Title:
|
Chief Financial Officer
(Principal Financial and Accounting Officer)
|
29